WE CLAIM:

- 1. A chimeric immunomodulatory compound (CIC) that stimulates production of IFN-α from human peripheral blood mononuclear cells, said CIC comprising at least three nucleic acid moieties, at least one of which comprises a sequence 5'-TCGY, where Y is selected from the group consisting of XCGX, XTCG, XXCG, and CGXX, where X is any nucleotide, and at least one nonnucleic acid spacer moiety.
- 2. The CIC of claim 1 comprising at least one multivalent nonnucleic acid spacer moiety.
- 3. The CIC of claim 1 wherein at least one nonnucleic acid spacer moiety comprises HEG, TEG, propyl, butyl, hexyl, pentaerythritol, 2-(hydroxymethyl)ethyl, glycerol, a polysaccharide, 1,3-diamino-2-propanol, or a dendrimer.
- 4. A CIC that stimulates production of IFN-α from human peripheral blood mononuclear cells but does not stimulate human B cell proliferation.
- 5. The CIC of claim 4 comprising a nucleic acid moiety comprising the sequence 5'-TCGAX_N, where X is any nucleotide and n is 1, 2, or 3.
- 6. The CIC of claim 5 wherein the nucleic acid moiety comprising the sequence 5'-TCGAX_N, where X is any nucleotide and n is an integer from 4 to 9.
- 7. The CIC of claim 5 comprising a nucleic acid moiety comprising the sequence 5'-TCGACGX_N, where X is any nucleotide and n is 1, 2, 3, or an integer from 4 to 7.

- 8. The CIC of claim 7 wherein N is 1.
- 9. The CIC of claim 8 wherein X is T.
- 10. The CIC of claim 9 having the structure (5'-TCGACGT-HEG)₂-glycerol-HEG-5'-TCGACGT or (5'-TCGACGT-HEG)₃-trebler-HEG-5'-TCGACGT.
- 11. A composition comprising a CIC of claim 4 and a pharmaceutically acceptable excipient.
- 12. A composition comprising a CIC of claim 11 and further comprising an antigen.
- 13. A composition comprising a CIC of claim 11 and further comprising a cationic microsphere.
- 14. A method of modulating an immune response in an individual comprising administering to an individual a CIC of claim 1 in an amount sufficient to modulate an immune response in said individual.
- 15. A method of modulating an immune response in an individual comprising administering to an individual a CIC of claim 4 in an amount sufficient to modulate an immune response in said individual.